S'abonner

Molecular surveillance of norovirus, 2005–16: an epidemiological analysis of data collected from the NoroNet network - 24/04/18

Doi : 10.1016/S1473-3099(18)30059-8 
Janko van Beek, MSc a, b, Miranda de Graaf, PhD a, Haider Al-Hello, PhD c, David J Allen, PhD d, e, f, Katia Ambert-Balay, PhD g, h, Nadine Botteldoorn, PhD i, Mia Brytting, PhD j, Javier Buesa, ProfMD k, Maria Cabrerizo, PhD l, m, Martin Chan, PhD n, Fiona Cloak, BA o, Ilaria Di Bartolo, PhD p, Susana Guix, PhD q, Joanne Hewitt, PhD r, Nobuhiro Iritani, PhD s, Miao Jin, ProfPhD t, Reimar Johne, ProfPhD u, Ingeborg Lederer, PhD v, Janet Mans, PhD w, Vito Martella, PhD x, Leena Maunula, PhD y, Georgina McAllister, PhD z, Sandra Niendorf, PhD aa, Hubert G Niesters, ProfPhD ab, Alexander T Podkolzin, PhD ac, Mateja Poljsak-Prijatelj, PhD ad, Lasse Dam Rasmussen, PhD ae, Gábor Reuter, ProfMD af, Gráinne Tuite, MSc ag, Annelies Kroneman, DVM b, Harry Vennema, PhD b, Marion P G Koopmans, ProfPhD a, b,
on behalf of

NoroNet

a Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands 
b Centre for Infectious Diseases Research, Diagnostics and Screening, National Institute of Public Health and the Environment, Bilthoven, Netherlands 
c Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland 
d Virus Reference Department, Public Health England, London, UK 
e Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK 
f Health Protection Research Unit in Gastrointestinal Infections, National Institute for Health Research, UK 
g National Reference Centre for Gastroenteritis Viruses, University Hospital of Dijon Bourgogne, Dijon, France 
h AgroSup Dijon PAM UMR A 02.102, University Bourgogne Franche-Comté, Dijon, France 
i Scientific Service of Foodborne Pathogens, Institute of Public Health, Brussels, Belgium 
j Microbial Typing Unit, The Public Health Agency of Sweden, Stockholm, Sweden 
k Viral Gastroenteritis Research Group, Department of Microbiology, University of Valencia, Valencia, Spain 
l Enterovirus and Viral Gastroenteritis Unit, Instituto de Salud Carlos III, Madrid, Spain 
m Translational Research Network in Pediatric Infectious Diseases, Instituto de Investigación Sanitaria de la Paz, Madrid, Spain 
n Department of Microbiology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong Special Administrative Region, China 
o Gastroenteric, Vectorborne and Zoonotic Unit, Health Protection Surveillance Centre, Dublin, Ireland 
p Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanita, Rome, Italy 
q Enteric Virus Laboratory, University of Barcelona, Barcelona, Spain 
r Norovirus Reference Laboratory, Institute of Environmental Science and Research, Porirua, New Zealand 
s Department of Microbiology, Osaka Institute of Public Health, Osaka, Japan 
t Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, China, Beijing, China 
u Department of Biological Safety, German Federal Institute for Risk Assessment, Berlin, Germany 
v Reference Centres and Reference Laboratories, Austrian Agency for Health and Food Safety, Vienna, Austria 
w Department of Medical Virology, University of Pretoria, Pretoria, South Africa 
x Department of Veterinary Medicine, University of Bari, Bari, Italy 
y Department of Food Hygiene and Environmental Health, University of Helsinki, Helsinki, Finland 
z Specialist Virology Centre, Royal Infirmary Edinburgh, Edinburgh, UK 
aa Consultant Laboratory for Noroviruses, Robert Koch Institute, Berlin, Germany 
ab Department of Medical Microbiology, Division of Clinical Virology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands 
ac RussianFederal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Central Research Institute of Epidemiology, Moscow, Russia 
ad Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia 
ae Department of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark 
af Department of Medical Microbiology and Immunology, Medical School, University of Pécs, Pécs, Hungary 
ag National Virus Reference Laboratory, University College Dublin, Dublin, Ireland 

* Correspondence to: Prof Marion P G Koopmans, Department of Viroscience, Erasmus Medical Center, PO Box 3015 CE, Rotterdam, Netherlands Correspondence to: Prof Marion P G Koopmans, Department of Viroscience Erasmus Medical Center PO Box 3015 CE Rotterdam Netherlands

Summary

Background

The development of a vaccine for norovirus requires a detailed understanding of global genetic diversity of noroviruses. We analysed their epidemiology and diversity using surveillance data from the www.noronet.nl.

Methods

We included genetic sequences of norovirus specimens obtained from outbreak investigations and sporadic gastroenteritis cases between 2005 and 2016 in Europe, Asia, Oceania, and Africa. We genotyped norovirus sequences and analysed sequences that overlapped at open reading frame (ORF) 1 and ORF2. Additionally, we assessed the sampling date and country of origin of the first reported sequence to assess when and where novel drift variants originated.

Findings

We analysed 16 635 norovirus sequences submitted between Jan 1, 2005, to Nov 17, 2016, of which 1372 (8·2%) sequences belonged to genotype GI, 15 256 (91·7%) to GII, and seven (<0·1%) to GIV.1. During this period, 26 different norovirus capsid genotypes circulated and 22 different recombinant genomes were found. GII.4 drift variants emerged with 2–3-year periodicity up to 2012, but not afterwards. Instead, the GII.4 Sydney capsid seems to persist through recombination, with a novel recombinant of GII.P16–GII.4 Sydney 2012 variant detected in 2014 in Germany (n=1) and the Netherlands (n=1), and again in 2016 in Japan (n=2), China (n=8), and the Netherlands (n=3). The novel GII.P17–GII.17, first reported in Asia in 2014, has circulated widely in Europe in 2015–16 (GII.P17 made up a highly variable proportion of all sequences in each country [median 11·3%, range 4·2–53·9], as did GII.17 [median 6·3%, range 0–44·5]). GII.4 viruses were more common in outbreaks in health-care settings (2239 [37·2%] of 6022 entries) compared with other genotypes (101 [12·5%] of 809 entries for GI and 263 [13·5%] of 1941 entries for GII non-GII.Pe–GII.4 or GII.P4–GII.4).

Interpretation

Continuous changes in the global norovirus genetic diversity highlight the need for sustained global norovirus surveillance, including assessment of possible immune escape and evolution by recombination, to provide a full overview of norovirus epidemiology for future vaccine policy decisions.

Funding

European Union’s Horizon 2020 grant COMPARE, ZonMw TOP grant, the Virgo Consortium funded by the Dutch Government, and the Hungarian Scientific Research Fund.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 5

P. 545-553 - mai 2018 Retour au numéro
Article précédent Article précédent
  • Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study
  • Gabriella Ferlazzo, Erika Mohr, Chinmay Laxmeshwar, Catherine Hewison, Jennifer Hughes, Sylvie Jonckheere, Naira Khachatryan, Virginia De Avezedo, Lusine Egazaryan, Amir Shroufi, Stobdan Kalon, Helen Cox, Jennifer Furin, Petros Isaakidis
| Article suivant Article suivant
  • Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study
  • R Scott McClelland, Jairam R Lingappa, Sujatha Srinivasan, John Kinuthia, Grace C John-Stewart, Walter Jaoko, Barbra A Richardson, Krista Yuhas, Tina L Fiedler, Kishorchandra N Mandaliya, Matthew M Munch, Nelly R Mugo, Craig R Cohen, Jared M Baeten, Connie Celum, Julie Overbaugh, David N Fredricks

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.